Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 0 Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Alzheimer's Disease and Other Tauopathies

NCT02531360 is registered in ClinicalTrials.gov with Molecular NeuroImaging as lead sponsor.

NCT NCT02531360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02531360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 0 Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Alzheimer's Disease and Other Tauopathies
Lead sponsor
Molecular NeuroImaging
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2015
Completion date
August 31, 2016
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease (ad), cortical basal syndrome (cbs), frontal temporal dementia (ftd), progressive supranuclear palsy (psp)